Lexicon Pharmaceuticals (LXRX) concentration risks

Lexicon Pharmaceuticals' concentration risk is dominated by its reliance on a single product, INPEFA (sotagliflozin), whose commercialization is central to the business — a high-disclosed-size exposure with both structural and dependency characteristics, since the company's fortunes are tied to one drug's commercial success. That single-product reliance is compounded by supply-chain concentration: Lexicon depends on a sole source third-party contract manufacturer in North America to manufacture, package, and label finished INPEFA product, and on a single third-party logistics provider, using two distribution locations, for shipping and warehousing — both high-disclosed-size dependency exposures where any single-point failure could directly disrupt commercial supply. On the demand side, INPEFA is sold principally to a limited number of major wholesalers, alongside selected regional wholesalers, a medium-sized dependency that adds another layer of counterparty concentration. Together, these exposures compound rather than diversify: a single product, a single manufacturer, and a single logistics provider all sit on the same critical path, meaning any disruption at one node has few alternatives to fall back on. This tightly coupled structure is the exposure most likely to move the verdict, since the wholesaler concentration is comparatively minor next to the manufacturing and logistics single points of failure.

For the engine’s reasoning on LXRX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.